Pipelines under development
We are developing following products.
BCL-101 is an anti-cancer DDS drug targeted for hepatocytoma, a disease with no effective pharmaceutical agent is available by systemic administration. The active ingredient of the drug is doxorubicin which is encapsulated in BNC-liposome. BCL-101 can exert its effect not only passively though the EPR effect (an effect that small size particles gather in tumor tissues which is seen in Doxil, a recently approved anti-cancer DDS drug) but also actively through the hepatocyte-targeting and the internalization effects of BNC. We believe BCL-101, as a second generation DDS drug, should show superior effect and lower toxicity than Doxil. BCL-101 has several superior characteristics over Doxil as examined by pharmacological and phamacodynamics studies in vitro and in vivo.
This system, by utilizing BNC-Liposome technology, aims to deliver siRNA into target cells in vivo for both the research and clinical use. From the study conducted so far, we produced a BNC-Liposome complex containing siRNA. The encapsulation efficiency of siRNA into the complex is high. The complex showed target cell-specific siRNA delivery and knock-down effect in vitro. We are now started studies to examine the knock-down effect in vivo.
This system is under development for in vivo plasmid DNA delivery specific to target cells. The results obtained so for indicated that a BNC-Liposome complex containing plasmid DNAs such as GFP, luciferase, and DS-Red, when added into medium, expresses these gene-derived proteins in hepatic cells, but not other cells, with high efficiency. We are now started studies to examine target cell-specific expression in vivo. The system is underdevelopment for both the in vivo research and clinical use.
We have scceeded to produce protein-incorporated BNC. By using this system you can incorporate any desired protein into BNC, and using the intrinsic ability of BNC, you can introduce the protein into targeted cells physiologically. We believe that this system can not only be used for reseraches for intracellular function of a protein, but also opens a new protein pharmaceuticals that works in the cells.
By using the advantage of BNC to recognize target cells in vivo, we just started the project to develop fluorescent probes for in vivo imaging. The probe is made from BNC-ZZ and BNC-Bio that are labeled by fluorescent dye. The BNC-ZZ probes are designed to observe cells and tissues by added antibody-specific manner and BNC-Bio by added sugar-chain, lectins, and peptides etc. The probes can be customized by end-users by simply select the antibody or cell-recognizing molecules. The probes will be primarily developed for research use, but the clinical use is also in future scope.
① BCL-101 (or BNC-D)
BCL-101 is an anti-cancer DDS drug targeted for hepatocytoma, a disease with no effective pharmaceutical agent is available by systemic administration. The active ingredient of the drug is doxorubicin which is encapsulated in BNC-liposome. BCL-101 can exert its effect not only passively though the EPR effect (an effect that small size particles gather in tumor tissues which is seen in Doxil, a recently approved anti-cancer DDS drug) but also actively through the hepatocyte-targeting and the internalization effects of BNC. We believe BCL-101, as a second generation DDS drug, should show superior effect and lower toxicity than Doxil. BCL-101 has several superior characteristics over Doxil as examined by pharmacological and phamacodynamics studies in vitro and in vivo.
② in vivo siRNA delivery system
This system, by utilizing BNC-Liposome technology, aims to deliver siRNA into target cells in vivo for both the research and clinical use. From the study conducted so far, we produced a BNC-Liposome complex containing siRNA. The encapsulation efficiency of siRNA into the complex is high. The complex showed target cell-specific siRNA delivery and knock-down effect in vitro. We are now started studies to examine the knock-down effect in vivo.
③ in vivo plasmid DNA delivery system
This system is under development for in vivo plasmid DNA delivery specific to target cells. The results obtained so for indicated that a BNC-Liposome complex containing plasmid DNAs such as GFP, luciferase, and DS-Red, when added into medium, expresses these gene-derived proteins in hepatic cells, but not other cells, with high efficiency. We are now started studies to examine target cell-specific expression in vivo. The system is underdevelopment for both the in vivo research and clinical use.
④ Protein-incoporated BNC for introducing the protein into cells
We have scceeded to produce protein-incorporated BNC. By using this system you can incorporate any desired protein into BNC, and using the intrinsic ability of BNC, you can introduce the protein into targeted cells physiologically. We believe that this system can not only be used for reseraches for intracellular function of a protein, but also opens a new protein pharmaceuticals that works in the cells.
⑤ Fluorescent in vivo imaging probes
By using the advantage of BNC to recognize target cells in vivo, we just started the project to develop fluorescent probes for in vivo imaging. The probe is made from BNC-ZZ and BNC-Bio that are labeled by fluorescent dye. The BNC-ZZ probes are designed to observe cells and tissues by added antibody-specific manner and BNC-Bio by added sugar-chain, lectins, and peptides etc. The probes can be customized by end-users by simply select the antibody or cell-recognizing molecules. The probes will be primarily developed for research use, but the clinical use is also in future scope.
｜